Accuray Inc (ARAY) Stock Analysis and Metrics

Accuray

NASDAQ: ARAY

$0.24 ▲ +0.00 (+0.13%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap29,832.96

P/E0.00

P/S0.00

Div. Yield0.00

ROIC (Qtr)-0.01

Total Debt (Qtr)145.18 Mn

Revenue Growth (1y) (Qtr)-68.32

Add ratio to table…

About

Accuray Incorporated is a radiation therapy company that develops manufactures sells and supports market changing solutions designed to deliver radiation treatments for complex cases while simplifying routine treatments. The company’s product portfolio includes the CyberKnife robotic system the TomoTherapy platform and its next generation Radixact system as well as the affordability focused Helix system. Accuray also provides related software for treatment planning data management and adaptive radiotherapy together with installation training and ongoing service contracts. Its technology incorporates artificial intelligence driven motion tracking that synchronizes the radiation beam with moving targets during treatment delivery. The firm aims to improve patient outcomes by enabling precise high dose radiation that spares healthy tissue and reduces the number of treatment fractions required. Through continuous innovation Accuray seeks to expand the use of radiation therapy beyond oncology to treat neurologic and endocrine disorders.

Accuray generates revenue primarily from the sale of its radiation delivery systems including the CyberKnife S7 and Radixact platforms. Additional income comes from the sale of software licences for treatment planning image guidance and adaptive therapy. The company also earns fees from installation services training programs and post contract support agreements that cover warranty and post warranty periods. Revenue is further supplemented by the joint venture in China that manufactures and sells locally branded radiotherapy systems. Service contracts provide a recurring revenue stream that includes technical support parts replacement and system upgrades. Training revenue is generated by educating clinicians physicists and dosage specialists on the safe and effective operation of the equipment. The company’s geographic diversification helps balance sales cycles across different regions and reduces reliance on any single market.

Accuray competes in the radiation therapy market against larger established firms such as Varian which is part of Siemens Healthineers and Elekta AB. The company differentiates itself through its robotic delivery technology that enables non isocentric beam angles and real time tumor tracking via its Synchrony system. Accuray’s platforms also provide integrated imaging that produces diagnostic quality CT images at low dose and workflow software that speeds treatment planning and delivery. These capabilities aim to improve treatment accuracy reduce side effects and increase patient throughput giving the company a competitive edge in both radiosurgery and conventional radiotherapy. The firm invests heavily in research and development to introduce new features such as AI driven auto contouring and enhanced image reconstruction. Its intellectual property portfolio includes over five hundred patents and patent applications covering key aspects of the CyberKnife and TomoTherapy technologies. Strong clinical evidence and peer reviewed publications support the safety and efficacy of its systems which helps win acceptance among physicians and payers. Nevertheless the company faces pressure from competitors that have greater financial resources and broader product lines.

The company serves hospitals free standing cancer treatment centers and academic medical centers that have radiation oncology departments. Its customers also include neurosurgery groups that use the CyberKnife system for intracranial and spinal lesion treatment. Accuray’s client base spans domestic and international markets with installations in North America Europe Asia and the Middle East. In the United States the majority of sales are made directly to hospitals and stand alone treatment facilities through a dedicated sales force. Outside the United States the company relies on a mix of direct sales representatives and distributors to reach customers in Western Europe Japan India and Canada. The joint venture in China further expands its presence in the world’s largest healthcare market by offering locally manufactured systems that meet regional regulatory requirements. By addressing both public and private healthcare providers Accuray aims to increase the adoption of its advanced radiation therapy solutions worldwide.

Investment Thesis

▲ Bull case

The transformation plan launched in December is already delivering measurable cost savings with approximately ten million dollars of margin improvements realized through the third quarter, exceeding the original twelve million target for fiscal 2026. Management expects the initiative to generate about twenty five million dollars of annualized operating profit improvement, with the bulk of the benefit appearing in fiscal 2027 and 2028. This structural cost reduction should lift gross margins and drive adjusted EBITDA toward positive territory as the savings flow through the income statement. The early success suggests the market may be underestimating the speed at which Accuray can turn its cost base into a sustainable profit engine.
The ten year strategic collaboration with the University of Wisconsin School of Medicine and Public Health leverages Accuray’s Stellar adaptive radiation therapy platform to build a real world clinical evidence engine. By accessing hundreds of thousands of treatment fractions from the installed base, the partnership aims to quantify the value of real time tumor motion management and inform future product development. This effort not only reinforces Accuray’s technological differentiation but also creates a potential barrier to entry for competitors who lack comparable data assets. The long term nature of the agreement positions the company to capture recurring revenue from licensing, co development fees and premium service contracts tied to proven clinical outcomes.
Paul Miele’s appointment as Chief Commercial Officer brings more than two decades of experience leading global capital medical device businesses across the Americas EMEA and APAC regions. In prior roles his leadership helped reverse revenue decline trends and delivered double digit annual growth, suggesting he can replicate that success at Accuray. His focus on expanding service and solutions monetization, reactivating the installed base and accelerating capital equipment sales aligns directly with the company’s stated priorities. The market may be overlooking the near term impact of his commercial leadership on top line acceleration and margin improvement.
Accuray is expanding its service portfolio beyond traditional maintenance by launching training and educational solutions that can be bundled into service agreements or sold standalone. Additionally the company plans to add software solutions to service contracts, which should increase recurring revenue streams and deepen customer engagement. These initiatives aim to monetize the large and growing installed base, turning service from a cost center into a higher margin growth driver. If successful the service business could offset product revenue volatility and provide a more predictable cash flow profile.
A renewed focus on distributor partnerships includes the appointment of a Vice President of Distributor Partnerships and the implementation of clear performance standards, improved transparency and stronger alignment. By tying distributor compensation to measurable outcomes Accuray expects to drive consistent high quality execution in markets where third party channels are essential. This structured approach should reduce channel friction, improve win rates and increase the effectiveness of the sales force. The market may not yet be pricing in the potential uplift from a more disciplined distributor network.

The transformation plan launched in December is already delivering measurable cost savings with approximately ten million dollars of margin improvements realized through the third quarter, exceeding the original twelve million target for fiscal 2026. Management expects the initiative to generate about twenty five million dollars of annualized operating profit improvement, with the bulk of the benefit appearing in fiscal 2027 and 2028. This structural cost reduction should lift gross margins and drive adjusted EBITDA toward positive territory as the savings flow through the income statement. The early success suggests the market may be underestimating the speed at which Accuray can turn its cost base into a sustainable profit engine.
The ten year strategic collaboration with the University of Wisconsin School of Medicine and Public Health leverages Accuray’s Stellar adaptive radiation therapy platform to build a real world clinical evidence engine. By accessing hundreds of thousands of treatment fractions from the installed base, the partnership aims to quantify the value of real time tumor motion management and inform future product development. This effort not only reinforces Accuray’s technological differentiation but also creates a potential barrier to entry for competitors who lack comparable data assets. The long term nature of the agreement positions the company to capture recurring revenue from licensing, co development fees and premium service contracts tied to proven clinical outcomes.
Paul Miele’s appointment as Chief Commercial Officer brings more than two decades of experience leading global capital medical device businesses across the Americas EMEA and APAC regions. In prior roles his leadership helped reverse revenue decline trends and delivered double digit annual growth, suggesting he can replicate that success at Accuray. His focus on expanding service and solutions monetization, reactivating the installed base and accelerating capital equipment sales aligns directly with the company’s stated priorities. The market may be overlooking the near term impact of his commercial leadership on top line acceleration and margin improvement.
Accuray is expanding its service portfolio beyond traditional maintenance by launching training and educational solutions that can be bundled into service agreements or sold standalone. Additionally the company plans to add software solutions to service contracts, which should increase recurring revenue streams and deepen customer engagement. These initiatives aim to monetize the large and growing installed base, turning service from a cost center into a higher margin growth driver. If successful the service business could offset product revenue volatility and provide a more predictable cash flow profile.
A renewed focus on distributor partnerships includes the appointment of a Vice President of Distributor Partnerships and the implementation of clear performance standards, improved transparency and stronger alignment. By tying distributor compensation to measurable outcomes Accuray expects to drive consistent high quality execution in markets where third party channels are essential. This structured approach should reduce channel friction, improve win rates and increase the effectiveness of the sales force. The market may not yet be pricing in the potential uplift from a more disciplined distributor network.

▼ Bear case

Persistent geopolitical disruptions in the Middle East North Africa and China continue to delay product shipments and suppress service revenue, creating a recurring headwind that management has not quantified in its guidance. The indefinite nature of these delays makes it difficult to forecast when installations will resume, leaving a material amount of potential revenue stuck in the backlog. Service margins in these regions are also being eroded by higher logistics costs and tariff related expenses. Until the external environment stabilizes, the company’s top line may remain constrained despite internal improvement efforts.
Service gross margin fell to 26.1% in the third quarter, down from 33.3% a year earlier, driven by higher net parts consumption of three point two million dollars and additional tariff impacts of zero point eight million dollars. These cost pressures reflect ongoing supply chain challenges and trade policy volatility that could persist beyond the current quarter. If parts consumption remains elevated or tariffs stay unfavorable, service profitability may stay depressed, offsetting gains from cost reduction initiatives. The market may be underestimating the durability of these margin headwinds.
Order backlog declined to approximately three hundred fifty six million dollars at quarter end, representing a twenty one% decrease compared with the prior year period. The book to bill ratio settled at one point zero in the third quarter, indicating that orders are just matching shipments and not building excess coverage. A stagnant or shrinking backlog limits near term revenue visibility and raises concerns about demand acceleration. Investors should consider the possibility that the current order environment reflects deeper market weakness rather than a temporary setback.
Restructuring and transformation related expenses remain elevated, with six point five million dollars of non recurring charges recognized in the third quarter alone. While management expects these costs to decline over the remainder of the fiscal year, the near term impact on operating income is significant and has contributed to the reported operating loss. The timing of when the anticipated cost savings will fully flow through the income statement is uncertain, which could delay the expected profitability turnaround. Market optimism about rapid margin expansion may be premature if restructuring charges linger.
The company’s future performance increasingly hinges on the execution of the newly appointed Chief Commercial Officer Paul Miele and Chief Legal Officer David Shin, whose inducement awards include substantial performance based restricted stock units tied to fiscal 2028 targets. If the leadership team fails to meet the aggressive performance thresholds, the awards may not vest, potentially leading to disappointment and a perception of overpaying for talent. Moreover, the dilution from the large RSU and PSU grants could weigh on earnings per share if the underlying performance does not materialize. This introduces execution risk that the market may not be fully pricing in.

Persistent geopolitical disruptions in the Middle East North Africa and China continue to delay product shipments and suppress service revenue, creating a recurring headwind that management has not quantified in its guidance. The indefinite nature of these delays makes it difficult to forecast when installations will resume, leaving a material amount of potential revenue stuck in the backlog. Service margins in these regions are also being eroded by higher logistics costs and tariff related expenses. Until the external environment stabilizes, the company’s top line may remain constrained despite internal improvement efforts.
Service gross margin fell to 26.1% in the third quarter, down from 33.3% a year earlier, driven by higher net parts consumption of three point two million dollars and additional tariff impacts of zero point eight million dollars. These cost pressures reflect ongoing supply chain challenges and trade policy volatility that could persist beyond the current quarter. If parts consumption remains elevated or tariffs stay unfavorable, service profitability may stay depressed, offsetting gains from cost reduction initiatives. The market may be underestimating the durability of these margin headwinds.
Order backlog declined to approximately three hundred fifty six million dollars at quarter end, representing a twenty one% decrease compared with the prior year period. The book to bill ratio settled at one point zero in the third quarter, indicating that orders are just matching shipments and not building excess coverage. A stagnant or shrinking backlog limits near term revenue visibility and raises concerns about demand acceleration. Investors should consider the possibility that the current order environment reflects deeper market weakness rather than a temporary setback.
Restructuring and transformation related expenses remain elevated, with six point five million dollars of non recurring charges recognized in the third quarter alone. While management expects these costs to decline over the remainder of the fiscal year, the near term impact on operating income is significant and has contributed to the reported operating loss. The timing of when the anticipated cost savings will fully flow through the income statement is uncertain, which could delay the expected profitability turnaround. Market optimism about rapid margin expansion may be premature if restructuring charges linger.
The company’s future performance increasingly hinges on the execution of the newly appointed Chief Commercial Officer Paul Miele and Chief Legal Officer David Shin, whose inducement awards include substantial performance based restricted stock units tied to fiscal 2028 targets. If the leadership team fails to meet the aggressive performance thresholds, the awards may not vest, potentially leading to disappointment and a perception of overpaying for talent. Moreover, the dilution from the large RSU and PSU grants could weigh on earnings per share if the underlying performance does not materialize. This introduces execution risk that the market may not be fully pricing in.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password